Goldman Sachs Keeps Sell Rating on Intercept Pharmaceuticals (ICPT), 'documents suggest challenging outlook for Ocaliva in NASH'
Tweet Send to a Friend
Goldman Sachs analyst Salveen Richter reiterated a Sell rating and $12.00 price target on Intercept Pharmaceuticals (NASDAQ: ICPT)The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
